Mostrando entradas con la etiqueta Actos. Mostrar todas las entradas
Mostrando entradas con la etiqueta Actos. Mostrar todas las entradas

martes, 1 de mayo de 2012

Canada Adds Warning for Actos Bladder Cancer as U.S. Actos Lawsuits Mount - Albany Times Union

The Actos Resource Center is the Web’s largest source for information on Actos research, side effects and legal news. Visit http://www.ActosCancer.com

(PRWEB) April 27, 2012

The Actos Resource Center, a consumer advocacy group, is alerting patients in the United States of an additional warning issued over the safety of Actos by Canada’s top drug regulatory agency.

Health Canada issued a warning on April 19, 2012 that the diabetes drug Actos may cause an increased risk of bladder cancer. Authorities there also stated they had come to an agreement with Takeda Pharmaceuticals, maker of the drug, to add a label warning addressing the risk.

The Canadian agency functions in much the same way as the FDA in the United States, who issued a similar warning associating Actos with bladder cancer on June 15, 2011.

According to The Canadian Press on April 19, 2012, the latest warning was issued in response to a study by Health Canada which was commenced last June, finding users of Actos are more than 40% more likely to develop bladder cancer.

The news is the latest in a string of warnings over Actos. Last year, CBS News reported on June 10, 2011 that Germany and France had banned Actos prescriptions after a study by the French Medicines Agency indicated long-term use could increase bladder cancer occurrences by as much as 40 percent.

In the United States, Takeda faces growing litigation concerns. Bloomberg reported on March 13, 2012 that as many as 10,000 patients may eventually file an Actos bladder cancer lawsuit. In December, a federal Judicial Panel on Multidistrict Litigation issued an order consolidating all lawsuits to a federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).

The Actos Resource Center urges anyone who has taken Actos to monitor for bladder cancer symptoms, and anyone who has been affected by bladder cancer to learn about their legal options.

The Actos Bladder Cancer Center only works with qualified Actos lawyers named to the Actos Plaintiff Steering Committee leading this litigation.

For more information on the research, warnings, side effects and legal news pertaining to the drug Actos, or for a recommendation of the top Actos lawyers, visit ActosCancer.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebactos/bladder-cancer/prweb9437804.htm


View the original article here

Canada Adds Warning for Actos Bladder Cancer as U.S. Actos Lawsuits Mount - Virtual-Strategy Magazine

 The Actos Resource Center is the Web’s largest source for information on Actos research, side effects and legal news. Visit http://www.ActosCancer.com(PRWEB) April 27, 2012


The Actos Resource Center, a consumer advocacy group, is alerting patients in the United States of an additional warning issued over the safety of Actos by Canada’s top drug regulatory agency.


Health Canada issued a warning on April 19, 2012 that the diabetes drug Actos may cause an increased risk of bladder cancer. Authorities there also stated they had come to an agreement with Takeda Pharmaceuticals, maker of the drug, to add a label warning addressing the risk.


The Canadian agency functions in much the same way as the FDA in the United States, who issued a similar warning associating Actos with bladder cancer on June 15, 2011.


According to The Canadian Press on April 19, 2012, the latest warning was issued in response to a study by Health Canada which was commenced last June, finding users of Actos are more than 40% more likely to develop bladder cancer.


The news is the latest in a string of warnings over Actos. Last year, CBS News reported on June 10, 2011 that Germany and France had banned Actos prescriptions after a study by the French Medicines Agency indicated long-term use could increase bladder cancer occurrences by as much as 40 percent.


In the United States, Takeda faces growing litigation concerns. Bloomberg reported on March 13, 2012 that as many as 10,000 patients may eventually file an Actos bladder cancer lawsuit. In December, a federal Judicial Panel on Multidistrict Litigation issued an order consolidating all lawsuits to a federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).


The Actos Resource Center urges anyone who has taken Actos to monitor for bladder cancer symptoms, and anyone who has been affected by bladder cancer to learn about their legal options.


The Actos Bladder Cancer Center only works with qualified Actos lawyers named to the Actos Plaintiff Steering Committee leading this litigation.


For more information on the research, warnings, side effects and legal news pertaining to the drug Actos, or for a recommendation of the top Actos lawyers, visit ActosCancer.com.


For the original version on PRWeb visit: http://www.prweb.com/releases/prwebactos/bladder-cancer/prweb9437804.htm 


View the original article here

lunes, 19 de marzo de 2012

Takeda Hid Actos Bladder Cancer Risks, Whistleblower Case Says - Salient News

The U.S. District Judge F. Dennis Saylor issued an order to unseal a whistleblower case by a former Takeda Pharmaceuticals medical reviewer involving the failure to report bladder cancer and Congestive Heart Failure (CHF) adverse events for the diabetes drug Actos.


The whistleblower is Dr. Helen Ge, a medical doctor and former safety consultant to Takeda’s pharmacovigilance division. Dr. Ge worked to review adverse events and to identify and evaluate potential safety signals for the diabetes drug Actos, the only drug in the same class and competing with GlaxoSmithKline’s Avandia.


Dr. Ge had direct knowledge of the Actos bladder cancer risk and, according to the complaint, encountered resistance from her superiors when she tried to report bladder cancer as related to Actos. Takeda’s adverse event database for Actos held more than 100 bladder cancers reported to the company, but only 72 reported to the FDA, which Dr. Ge referred to as “a serious discrepancy.” Takeda, like other drug companies, is required to update the U.S. Food and Drug Administration’s Adverse Event Reporting System.


Takeda Pharmaceutical Co. failed to give accurate reports to regulators about hundreds of congestive heart failure cases associated with its diabetes drug Actos, Dr. Ge claimed in a lawsuit. Additionally, the company failed to classify “non-hospitalized or non- fatal” congestive heart failure cases as serious from late 2007 to January 2010, and supervisors directed the whistleblower to change her “related” assessment to unrelated.


According to her complain, Dr. Ge complained to her superiors that her medical assessments were being downgraded from “serious” to “non-serious” and that, as a result of this, the Congestive Heart Failure events were being under-reported to the FDA. As a result of her complaint, her contract with Takeda was terminated.


“Takeda’s motivation to fraudulently report and under-report the serious adverse events was driven by an economic desire to falsely enhance Actos’s safety profile and to increase sales,” Ge said. Takeda wanted to push that Actos was safer than GlaxoSmithKline Plc (GSK)’s Avandia diabetes drug, and that the company downplayed data suggesting a link between Actos and bladder cancer, according to the complaint.


In 2007, the FDA ordered Takeda and Glaxo to place its strongest warning on the labeling of their drugs about the risk of congestive heart failure, a condition that occurs when the heart doesn’t adequately pump blood. Avandia has since has been severely restricted in the U.S. Ge sued under the False Claims Act in 2010, and the suit was recently unsealed. The Justice Department decided not to intervene in the suit, after reviewing the claim, but the plaintiff hopes that additional evidence will be enough to persuade federal regulators to take a second look.



Nina, owner of NinaRotz.com, is a freelance writer and blogger. Nina’s work has been published and linked on Associated Content, Yahoo! Shine, Yahoo! Voices, eHow, Live Strong, CNN, USA Today, The Wall Street Journal, as well as various online magazines and blogs.


Tags: Actos, actos adverse failure, actos bladder cancer risks, actos heart, Avandia, bladder cancer, bladder cancer risks, Congestive Heart Failure, effects, Takeda, takeda whistleblower

View the original article here

sábado, 17 de marzo de 2012

Takeda Actos Judge Names Lead Attorneys in U.S. Bladder-Cancer Lawsuits - Bloomberg

The judge overseeing lawsuits alleging Takeda Pharmaceutical Co. (4502)’s Actos diabetes medicine causes cancer appointed 19 plaintiffs’ lawyers to manage litigation involving U.S. claims.

Takeda, Asia’s biggest drugmaker, may face as many as 10,000 claims that Actos causes bladder cancer after U.S. regulators found last year the drug was linked to the disease. Federal lawsuits against the drugmaker were consolidated before U.S. District Judge Rebecca Doherty in Lafayette, Louisiana, in December. The first hearing on the cases is set for March 22, according to court filings.

“The court has determined to effect the selection of lead counsel, liaison counsel and plaintiffs’ executive and steering committees before the March 22nd-23rd status conference,” Doherty said in a March 12 note posted on the court’s website.

The lawsuits claim patients who use Actos, a prescription drug approved to treat type 2 diabetes, face increased risks of developing bladder cancer. The plaintiffs also claim that Takeda and co-defendant Eli Lilly & Co., based in Indianapolis, withheld information about the risk and failed to provide adequate warnings.

Takeda pulled Actos, its top-selling drug, off the market in Germany and France last year after it was linked to an increased cancer risk. The medication had sales of 387.9 billion yen ($4.8 billion) last fiscal year, 27 percent of the Osaka, Japan-based company’s revenue.

“Given that litigation is pending, we can’t comment,” Jocelyn Gerst, a U.S.-based spokeswoman for Takeda, said in a telephone interview about the selection of the plaintiffs’ group.

Doherty named attorneys Richard Arsenault and Paul Pennock as lead plaintiffs’ counsel in the case and also appointed them to the executive committee, along with lawyers Mark Robinson and Hunter Shkolnik.

Arsenault, a products-liability lawyer based in Alexandria, Louisiana, served as one of the lead lawyers in consolidated cases filed against Merck & Co. (MRK) over its Vioxx painkiller that resulted in a $4.85 billion settlement in November 2007.

Pennock, a New York-based attorney, was one of the lawyers leading the consolidated suits against AstraZeneca Plc (AZN) over its Seroquel antipsychotic drug. The London-based drugmaker agreed last year to pay a total of about $350 million to resolve patients’ claims that the drug caused diabetes.

The Los Angeles-based Robinson, who has won multimillion- dollar jury awards against carmakers such as Ford Motor Co., is a co-lead counsel in sudden-acceleration lawsuits against Toyota Motor Corp. (7203)

Shkolnik, based in New York City, served as a member of the plaintiffs’ steering committee in lawsuits against Medtronic Inc. (MDT) over flawed heart defibrillators. The cases later settled for more than $114 million.

Other lawyers named to the plaintiffs’ steering committee in the Actos cases include Mark Lanier, a Texas-based lawyer who won the first jury award against Whitehouse Station, New Jersey- based Merck in the Vioxx litigation, and Chris Seeger, a New Jersey-based attorney who also won a verdict against Merck on behalf of Vioxx users.

The judge also named Andy Birchfield, an Alabama-based lawyer who helped negotiate the $4.85 billion Vioxx settlement, and Vance Andrus, a Lafayette-based lawyer who was one of the lead counsels in cases against GlaxoSmithKline Plc (GS) over its Avandia diabetes drug. The London-based drugmaker has agreed to pay more than $700 million to resolve claims that Avandia caused heart attacks and strokes in users.

The lawsuits are consolidated in In Re: Actos Products Liability Litigation, 11-2299, U.S. District Court, Western District of Louisiana (Lafayette).

To contact the reporters on this story: Jef Feeley in Wilmington, Delaware at jfeeley@bloomberg.net; Margaret Cronin Fisk in Detroit at mcfisk@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net


View the original article here